| アブストラクト | Isolated arthralgia, without hemorrhagic side effect, exists and is considered as a very rare adverse drug reaction according to vitamin K antagonists' (VKAs) summary of product characteristics. Up to now, there are no literature reports of isolated, nonhemorrhagic joint complications in patients receiving VKAs. Hence, the objective of this study was to describe cases of VKA-related nonhemorrhagic joint disorders (fluindione, warfarin, and acenocoumarol) reported in the French Pharmacovigilance Database (FPVD). Sixty-one reports (male : female ratio, 1.18; median [interquartile range (IQR)] age: 60 [49-72]) were found. Fluindione, warfarin, and acenocoumarol were respectively suspected in 42, 12, and 7 cases. Arthralgia was reported in 47 cases (77%), arthritis in nine cases (15%), capsulitis in three cases (5%), and bursitis in two cases (3%). Although the joint symptoms mainly concerned the lower limbs, all types of joints were affected. Arthralgia was associated with myalgia in 14 cases and with tendinitis in three cases. The median (IQR) time interval between VKA introduction and arthralgia onset was 26 (10-98) days (range: 1-6935). VKA was withdrawn in 44 cases, and a decrease in the intensity of joint symptoms was observed in 30 cases. In three cases, reintroduction of the same VKA led to the recurrence of symptoms. In view of the large prescription of this drug class worldwide, patients and clinicians (and especially primary care physicians and geriatricians) should be aware of this possible adverse drug reaction when confronted with joint disorders in patients of all ages taking VKAs. |
|---|
| 組織名 | CHU Lille, Centre Regional de Pharmacovigilance du Nord-Pas de Calais, F-59000,;Lille, France.;Universite de Lille 2, U1171, F-59000, Lille, France.;INSERM U1171, F-59000, Lille, France.;UFR de Medecine, Universite de Lille, F-59000, Lille, France.;CHU de Lille, Service de Medecine Interne, F-59000, Lille, France.;CHU de Lille, Centre National De Reference Maladies Systemiques et Auto-Immunes;Rares (Sclerodermie Systemique), F-59000, Lille, France.;Service de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire;et Faculte de Medecine de Toulouse, 31000, Toulouse, France.;Faculte de Medecine, INSERM, UMR 1027, Universite de Toulouse, 31000, Toulouse,;France.;Centre Midi-Pyrenees de PharmacoVigilance, de Pharmaco epidemiologie et;d'Informations sur le Medicament et Pharmacopole Midi-Pyrenees, 31000, Toulouse,;Centre Regional de Pharmacovigilance de Lyon, Hospices Civils de Lyon, 69000,;Lyon, France. |
|---|
